Literature DB >> 18769939

Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy.

Carmen Valbuena1, Elísio Carvalho, Manuela Bustorff, Mariana Ganhão, Sandra Relvas, Rosete Nogueira, Fátima Carneiro, João Paulo Oliveira.   

Abstract

Fabry disease is an X-linked glycosphingolipidosis caused by deficiency of alpha-galactosidase. Progressive chronic kidney disease (CKD) is a major cause of morbidity and mortality in males. Although 40% of heterozygous females may develop renal involvement, pathologic data on Fabry nephropathy in heterozygotes are scarce. We reviewed the kidney biopsies of four affected females who had normal to slightly sub-normal renal function, two of them with overt proteinuria. Chronic non-specific degenerative lesions and glycosphingolipid accumulation per cell type were semi-quantitatively assessed by light and electron microscopy. Cellular distribution of glycosphingolipid deposits was best assessed on semithin sections. Podocyte effacement was seen only in proteinuric patients. Combined analysis of our data with those of two earlier series showed that glomerular sclerosis and tubulointerstitial fibrosis are predictors of proteinuria and CKD stage. There was no histopathological evidence supporting a major role of vascular damage in the early pathogenesis of Fabry nephropathy in females.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18769939     DOI: 10.1007/s00428-008-0653-2

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  54 in total

1.  Acp. Best practice no 160. Renal biopsy specimens.

Authors:  P N Furness
Journal:  J Clin Pathol       Date:  2000-06       Impact factor: 3.411

2.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

Review 3.  Podocyte damage damages podocytes: autonomous vicious cycle that drives local spread of glomerular sclerosis.

Authors:  Iekuni Ichikawa; Ji Ma; Masaru Motojima; Taiji Matsusaka
Journal:  Curr Opin Nephrol Hypertens       Date:  2005-05       Impact factor: 2.894

4.  Fabry disease: a morphologic study of 11 cases.

Authors:  Edgar G Fischer; Michael J Moore; Donna J Lager
Journal:  Mod Pathol       Date:  2006-06-23       Impact factor: 7.842

5.  Early renal changes in hemizygous and heterozygous patients with Fabry's disease.

Authors:  M C Gubler; G Lenoir; J P Grünfeld; A Ulmann; D Droz; R Habib
Journal:  Kidney Int       Date:  1978-03       Impact factor: 10.612

6.  IgA nephropathy in two adolescent sisters heterozygous for Fabry disease.

Authors:  Catharina Whybra; Andreas Schwarting; Jörg Kriegsmann; Andreas Gal; Eugen Mengel; Christoph Kampmann; Frank Baehner; Ellen Schaefer; Michael Beck
Journal:  Pediatr Nephrol       Date:  2006-07-13       Impact factor: 3.714

7.  A nonsense mutation (R220X) in the alpha-galactosidase A gene detected in a female carrier of Fabry disease.

Authors:  C Meaney; L C Blanch; C P Morris
Journal:  Hum Mol Genet       Date:  1994-06       Impact factor: 6.150

Review 8.  Kidney in early atherosclerosis.

Authors:  Alejandro R Chade; Amir Lerman; Lilach O Lerman
Journal:  Hypertension       Date:  2005-05-16       Impact factor: 10.190

9.  Ultrastructural study of renal involvement in two females with Anderson-Fabry disease.

Authors:  A Tosoni; M Nebuloni; P Zerbi; L Vago; C Comotti; A Sessa
Journal:  Ultrastruct Pathol       Date:  2005 May-Aug       Impact factor: 1.094

10.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

View more
  17 in total

1.  Immunohistochemical diagnosis of Fabry nephropathy and localisation of globotriaosylceramide deposits in paraffin-embedded kidney tissue sections.

Authors:  Carmen Valbuena; Dina Leitão; Fátima Carneiro; João Paulo Oliveira
Journal:  Virchows Arch       Date:  2011-12-29       Impact factor: 4.064

2.  Kidney histologic alterations in α-Galactosidase-deficient mice.

Authors:  Carmen Valbuena; João Paulo Oliveira; Fátima Carneiro; Sandra Relvas; Mariana Ganhão; M Clara Sá-Miranda; Lorena G Rodrigues
Journal:  Virchows Arch       Date:  2011-02-16       Impact factor: 4.064

3.  A novel unbiased method reveals progressive podocyte globotriaosylceramide accumulation and loss with age in females with Fabry disease.

Authors:  Behzad Najafian; Aurelio Silvestroni; Alexey Sokolovskiy; Camilla Tøndel; Einar Svarstad; Bogdan Obrisca; Gener Ismail; Myrl D Holida; Michael Mauer
Journal:  Kidney Int       Date:  2022-04-26       Impact factor: 18.998

Review 4.  Lysosome dysfunction in the pathogenesis of kidney diseases.

Authors:  Kameswaran Surendran; Seasson P Vitiello; David A Pearce
Journal:  Pediatr Nephrol       Date:  2013-11-12       Impact factor: 3.714

5.  Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN).

Authors:  Agnes B Fogo; Leif Bostad; Einar Svarstad; William J Cook; Solange Moll; Federic Barbey; Laurette Geldenhuys; Michael West; Dusan Ferluga; Bojan Vujkovac; Alexander J Howie; Aine Burns; Roy Reeve; Stephen Waldek; Laure-Hélène Noël; Jean-Pierre Grünfeld; Carmen Valbuena; João Paulo Oliveira; Justus Müller; Frank Breunig; Xiao Zhang; David G Warnock
Journal:  Nephrol Dial Transplant       Date:  2009-10-15       Impact factor: 5.992

Review 6.  Understanding the gastrointestinal manifestations of Fabry disease: promoting prompt diagnosis.

Authors:  Claire Zar-Kessler; Amel Karaa; Katherine Bustin Sims; Virginia Clarke; Braden Kuo
Journal:  Therap Adv Gastroenterol       Date:  2016-04-15       Impact factor: 4.409

7.  Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation.

Authors:  David G Warnock; Alberto Ortiz; Michael Mauer; Gabor E Linthorst; João P Oliveira; Andreas L Serra; László Maródi; Renzo Mignani; Bojan Vujkovac; Dana Beitner-Johnson; Roberta Lemay; J Alexander Cole; Einar Svarstad; Stephen Waldek; Dominique P Germain; Christoph Wanner
Journal:  Nephrol Dial Transplant       Date:  2011-07-29       Impact factor: 5.992

8.  Epithelial-Mesenchymal Transition in Kidney Tubular Epithelial Cells Induced by Globotriaosylsphingosine and Globotriaosylceramide.

Authors:  Yeo Jin Jeon; Namhee Jung; Joo-Won Park; Hae-Young Park; Sung-Chul Jung
Journal:  PLoS One       Date:  2015-08-20       Impact factor: 3.240

Review 9.  Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring.

Authors:  Björn Hoffmann
Journal:  Orphanet J Rare Dis       Date:  2009-10-11       Impact factor: 4.123

10.  Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease.

Authors:  Fernando C Fervenza; Roser Torra; David G Warnock
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.